Biography
Ken Redekop, Ph.D. is an associate professor at the Institute for Medical Technology Assessment, Erasmus Universiteit Rotterdam, The Netherlands. He is a clinical epidemiologist with more than 20 years of experience in observational research, clinical trial analysis, and medical technology assessment and an author of over 100 papers in the medical literature. Current studies include early-stage cost-effectiveness analyses of medical devices and tests, RCT-based economic evaluations, economic evaluations in the Diagnostics Assessment programme of the National Institute for Health and Clinical Excellence (NICE, UK) and outcomes research studies to determine the effectiveness and cost-effectiveness of expensive medicines in daily practice. Most studies relate to diabetes, cardiovascular disease, and cancer, and most involve modelling and evidence synthesis.
Erasmus School of Health Policy & Management
Associate professor | Health Technology Assessment (HTA)
- redekop@eshpm.eur.nl
More information
Work
- Gimon de Graaf, Ivy Timmermans, Mathias Meine, Marco Alings, Susanne S Pedersen, Philippe Mabo, Edgar Zitron, Ken Redekop & Henneke Versteeg (2024) - Economic evaluation of remote monitoring of patients with an implantable cardiac defibrillator (REMOTE-CIED study) - Journal of Telemedicine and Telecare, 30 (7), 1173-1185 - doi: 10.1177/1357633X221129176 - [link]
- Bart Jan Boverhof, W. Ken Redekop, Jacob J. Visser, Carin A. Uyl-de Groot & Maureen P.M.H. Rutten-van Mölken (2024) - Broadening the HTA of medical AI: A review of the literature to inform a tailored approach - Health Policy and Technology, 13 (2) - doi: 10.1016/j.hlpt.2024.100868 - [link]
- Carlos Antonio Godoy Junior, Francesco Miele, Laura Mäkitie, Eleonora Fiorenzato, Maija Koivu, Lytske Jantien Bakker, Carin Uyl de Groot, William Ken Redekop & Welmoed Kirsten van Deen (2024) - Attitudes Toward the Adoption of Remote Patient Monitoring and Artificial Intelligence in Parkinson’s Disease Management: Perspectives of Patients and Neurologists - Patient, 17 (3), 275-285 - doi: 10.1007/s40271-023-00669-0 - [link]
- M. M.J. Galekop, J. Veldwijk, C. A. Uyl-de Groot & W. K. Redekop (2024) - Preferences and willingness to pay for personalized nutrition interventions: Discrete choice experiments in Europe and the United States - Food Quality and Preference, 113 - doi: 10.1016/j.foodqual.2023.105075 - [link]
- Milanne Maria Johanna Galekop, Josep Maria Del Bas, Philip C. Calder, Carin A. Uyl-De Groot & William Ken Redekop (2024) - A health technology assessment of personalized nutrition interventions using the EUnetHTA HTA Core Model - International Journal of Technology Assessment in Health Care, 40 (1) - doi: 10.1017/S0266462324000060 - [link]
- Bart Jan Boverhof, W. Ken Redekop, Daniel Bos, Martijn P.A. Starmans, Judy Birch, Andrea Rockall & Jacob J. Visser (2024) - Radiology AI Deployment and Assessment Rubric (RADAR) to bring value-based AI into radiological practice - Insights into Imaging, 15 (1) - doi: 10.1186/s13244-023-01599-z - [link]
- Milanne Maria Johanna Galekop, Carin Uyl-de Groot & William Ken Redekop (2023) - Economic Evaluation of a Personalized Nutrition Plan Based on Omic Sciences Versus a General Nutrition Plan in Adults with Overweight and Obesity: A Modeling Study Based on Trial Data in Denmark - PharmacoEconomics - Open, 8 (2), 313-331 - doi: 10.1007/s41669-023-00461-8 - [link]
- L. A. Visser, I. den Uijl, W. K. Redekop, M. Sunamura, M. Lenzen, E. Boersma, R. W.M. Brouwers, H. M.C. Kemps, H. J.G. van den Berg-Emons & N. ter Hoeve (2023) - Cost-Effectiveness of a Cardiac Rehabilitation Program Specifically Designed for Patients With Obesity Within the OPTICARE XL Randomized Controlled Trial - Archives of Physical Medicine and Rehabilitation, 104 (6), 855-862 - doi: 10.1016/j.apmr.2023.02.005 - [link]
- Remziye Zaim, Ken Redekop & Carin A Uyl-de Groot (2023) - Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment - Frontiers in Health Services, 3 - doi: 10.3389/frhs.2023.1034256 - [link]
- Remziye Zaim, W. Ken Redekop & Carin A. Uyl-de Groot (2023) - Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer - Frontiers in Oncology, 13, 1027659 - doi: 10.3389/fonc.2023.1027659 - [link]
- Carin Uyl - de Groot, Ken Redekop, Amir Ansaripour, K. Zendehdel, N. Tadayon & F. Sadeghi (2016) - Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran
Fellowship of Postgraduate Medicine
- Start date approval
- May 2024
- End date approval
- December 2024
- Place
- LONDON
- Description
- Editor-in-Chief
Master Thesis HE
- Year Level
- master, master
- Year
- 2024
- Course Code
- GW4592M
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2024
- Course Code
- GW4555M
Module Knowledge
- Level
- bachelor 2
- Year Level
- bachelor 2
- Year
- 2024
- Course Code
- GW205K
